Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Rafina Innovations Inc. | Financial_Report.xls |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
Amendment No. 1
|
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the quarterly period ended September 30, 2013
|
|
|
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period from __________ to __________
|
|
|
000-53089
|
|
|
Commission File Number
|
|
|
China Northern Medical Device, Inc.
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
|
30-0428006
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
Kolokotroni 2A. Paleo Faliro, Athens, Greece
|
17563
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(30) 698 1083600
|
|
|
(Registrant’s telephone number, including area code)
|
|
|
(Former name, former address and former fiscal year, if changed since last report)
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
|
Yes [X] No [ ]
|
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
|
Yes [ ] No [ X ]
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[ ]
|
|
Non-accelerated filer
|
[ ]
|
Smaller reporting company
|
[X]
|
|
(Do not check if a smaller reporting company)
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
|
Yes [ ] No [X ]
|
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities un der a plan confirmed by a court.
|
Yes [ ] No [ ]
|
APPLICABLE ONLY TO CORPORATE ISSUERS
|
3,550,000 common shares outstanding as of November 18, 2013
|
|
(Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.)
|
2
Explanatory Note
This Amendment No. 1 on Form 10-Q/A (this “Amendment”) of China Northern Medical Device, Inc. for the nine month period ended September 30, 2013 is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S–T.
This Amendment No. 1 to the Form 10-Q speaks as of the filing date of the Form 10-Q (the "Filing date"), does not reflect events that may have occurred subsequent to the filing date, and does not modify or update in any way disclosures made in the Form 10-Qas filed on November 19, 2013.
3
|
Exhibit Number
|
Description
|
|
|
31.1
|
Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, incorporated by reference to our Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on November 19, 2013.
|
|
|
31.2
|
Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, incorporated by reference to our Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on November 19, 2013.
|
|
|
32.1+
|
Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, incorporated by reference to our Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on November 19, 2013.
|
|
|
101.INS*
|
XBRL Instance Document
|
|
|
101.SCH*
|
XBRL Taxonomy Schema
|
|
|
101.CAL*
|
XBRL Taxonomy Calculation Linkbase
|
|
|
101.DEF*
|
XBRL Taxonomy Definition Linkbase
|
|
|
101.LAB*
|
XBRL Taxonomy Label Linkbase
|
|
|
101.PRE*
|
XBRL Taxonomy Presentation Linkbase
|
*Filed herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
+ In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
4
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
CHINA NORTHERN MEDICAL DEVICE, INC.
|
||
|
Date: November 20, 2013
|
By:
|
/s/ Sotirios Leontaritis
|
|
Sotirios Leontaritis
|
||
|
Chief Executive Officer and Chief Financial Officer
|
||
|
(Duly Authorized Officer, Principal Executive Officer and Principal Financial Officer)
|
||
5